cancer screening News
-
IONIQ hosts Salt Lake City Mayor Mendenhall at its Office
IONIQ Sciences, Inc. (“IONIQ” or the “Company”) was honored to welcome Salt Lake City Mayor Mendenhall to its office today. During the Mayor’s visit, Michael Garff, IONIQ COO, shared how the Company is developing a Multi-Cancer Screen to help physicians confidently accelerate their diagnoses to the earliest, most-treatable stages when money and lives can be saved. We ...
-
Breast imaging products help with coronavirus backlog
With the COVID-19 pandemic pushing breast cancer screening to the back burner for many patients, scanner and software manufacturers have more reason than ever to bring products to the market that make scans faster and more comfortable, and helping radiologists manage their growing worklists. Here’s a look at what’s new in the last year from more than a dozen companies. Koios Medical, ...
-
InHealth (North and East Devon NHS Breast Screening Unit) signing up to the AI in Health & Care Award with Kheiron Medical Technologies
InHealth, who provide services for North and East Devon NHS Breast Screening, has entered into the research agreement to work with Kheiron Medical Technologies as part of the AI in Health & Care Award. This partnership marks another significant step in the journey to build an evidence base to demonstrate the effectiveness and safety of artificial intelligence in NHS breast cancer screening. ...
-
Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch
Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for ...
-
It’s World Lung Cancer Day
August 1 marks World Lung Cancer Day -- a time to raise awareness of the need for increased lung cancer research and innovation. Anyone can get lung cancer. Here are the facts you need to know: Lung cancer is the leading cause of cancer deaths worldwide More patients die every year from lung cancer than from prostate, breast, and colon cancer combined The lung cancer five-year survival rate ...
-
The Chinese University of Hong Kong and Aurora Medical Technology Hong Kong to collaborate on breast cancer research program
Aurora Medical Technology Hong Kong (Aurora-HK) and The Chinese University of Hong Kong (CUHK) are pleased to announce the completion of a landmark collaboration agreement leveraging the shared interests and diverse expertise of the two entities. Led by Winnie chiu-wing Chu MD, Professor of radiology at CUHK and Abraham Morse MD, Medical Director of Aurora, the joint project will investigate the ...
-
Immundiagnostik`s Colorectal Cancer Screening Portfolio
Regular participation in colorectal cancer (CRC) screening programmes can reduce the number of colorectal cancer cases as well as mortality rates (Brenner et al., 2014; Zorzi et al., 2015)*. Quantitative Fecal Immunochemical Tests (FIT) are recommended for colorectal cancer population screenings. An advantage of quantitative tests is the ability to vary cut-off values, which allows an adaption to ...
-
Insights from the American Lung Association’s 2021 State of Lung Cancer Report
The American Lung Association recently released its 2021 State of Lung Cancer report. Lung cancer is the leading cause of cancer deaths worldwide because the disease is often diagnosed at the late stages. Early diagnosis of lung nodules can help patients get treatment sooner and improve long-term survival rates. Auris is committed to fighting this deadly disease by helping physicians diagnose ...
-
Save the Date: American cancer society corporate impact conference - June 9-10, 2011
Cancer touches more than 40 percent of Americans in their lifetime. With a total cost of nearly $264 billion in health care expenses and lost productivity in 2010, the disease has a major impact on the workforce. If you are responsible for your company's overall health management, health and wellness programs, corporate philanthropy, and/or community involvement initiatives, you can help change ...
-
Review our webinar: Clinical Validation of HPV assays on the NeuMoDx Platform
Self-screen’s Chief Scientific Officer dr. Bart Hesselink talks about the clinical validation of QIAGEN’s next generation HPV screening assay on the NeuMoDxTM Molecular Systems. The NeuMoDxTM 288 and NeuMoDxTM96 Molecular Systems are fully automated continuous random-access analyzers that perform adequately in standardized, high volume cervical cancer HPV screening laboratories. The ...
-
The Netherlands started QIAsure Methylation Test implementation trial for triage of HPV positively screened women
With the introduction of HPV based screening in 2017 the Dutch cervical cancer screening program underwent an important improvement. More women at risk are being discovered due to the higher sensitivity of HPV assays compared to the old cytology based test program, but as a consequence the number of referrals after cytology based triage of HPV positive women has increased 3 times. The ...
-
The largest breast AI study to date shows value of Transpara in mammographic screening
The Cancer Registry of Norway is one of the oldest and most respected organisations of its kind in the world. It collects data and produces statistics of the cancer prevalence in Norway, has the administrative responsibility for the public screening programme in Norway and has an extensive research activity. In a recent study, the Registry used over 120,000 screening examinations from a ...
-
QView Medical maintains leadership position in AI-powered breast cancer screening technology through alliance with GE Healthcare
QView Medical, a breast cancer detection pioneer and maker of the FDA-approved artificial intelligence (AI) software system for breast cancer screening, and GE Healthcare today announced that QView's QVCAD software can be launched on GE Healthcare's Invenia™ ABUS 2.0 (Automated Breast Ultrasound), which has an open platform technology that allows the integration of third-party AI tools for ...
-
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
Highly sensitive Shield test offers convenient screening method that can be completed with simple blood draw, helping overcome barriers to compliance Test demonstrated sensitivity of 91% in colorectal cancer and 20% in advanced adenoma detection with specificity of 92% in validation studies PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology ...
-
Cancer Prevention and Early Detection Is One Step Closer as Universal DX Announces Breakthrough Study Results from Its Multi-omics + Computational Biology + Machine Learning Blood Tes
New results from the OMICS study, which will be presented atASCO, show Universal DX's blood test can detect colorectal cancer with extraordinary accuracy (92% sensitivity / 97% specificity), which exceeds currently available non-invasive tests for colorectal cancer screening Early detection cancer screening via a liquid biopsy is not only critical to save lives, but is a vast market opportunity, ...
-
QView Medical Inc. Announces FDA PMA Approval for QVCAD for the GE Invenia 3D Automated Breast Ultrasound System (“ABUS”)
QView Medical is pleased to announce FDA approval for QVCAD to be used with the GE Invenia™ ABUS in breast screening for asymptomatic dense breasted women whose mammogram was negative. QVCAD is the next generation CAD system for automated breast ultrasound ("ABUS") based on deep learning algorithms. The QVCAD innovative C-Thru technology combined with ABUS has demonstrated a 33% improved ...
-
GRAIL Statement on President Biden’s Bold Initiative to Reignite the Cancer Moonshot
“We applaud President Biden for reigniting the Cancer Moonshot and highlighting the critical role of early detection in achieving the ambitious, but attainable, goal of reducing the cancer death rate by at least 50 percent in the next 25 years. Improving quality of life for patients and survivors, while addressing inequities in access to cancer screening, diagnostics and treatment is a ...
By Grail, Inc.
-
GRAIL and Premier’s PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Premier, Inc.’s PINC AI™, an advanced technology and services platform that provides artificial intelligence-enabled clinical performance improvement technologies, to support patient access to Galleri®, GRAIL’s groundbreaking multi-cancer early ...
By Grail, Inc.
-
Does volume matter? Impact of collection volumes on detection of biomarkers and HPV DNA in first-void urine
The study by Laura Téblick (University of Antwerp, Belgium) investigated whether varying first-void urine collection volumes, including 4, 10 and 20 mL collected with Colli-Pee, affects the detection of human and viral endpoints (i.e., glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β-actin (ACTB), β-globin (HBB) and Human Papillomavirus (HPV). The results showed that all ...
By Novosanis NV
-
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
Prospective registrational study expected to enroll nearly 10,000 patients in 36 months REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you